Drug Trial Radar · NCT07807475
DNP-MRSI of HCC Metabolism to Predict Therapeutic Response
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
232
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Sep 15, 2031
Study completion Sep 15, 2034
Sponsor
- Lead sponsor
- Abramson Cancer Center at Penn MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 8, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This proposal describes a non-therapeutic diagnostic clinical trial to estimate the ability of DNP-MRS imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism to predict response following LRT with TACE/TARE/Microwave Ablation or ST in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B or C HCC. The primary hypothesis is that intratumoral pyruvate, lactate, alanine and carbon dioxide/bicarbonate measured by DNP-MRSI correspond to cellular viability resulting from recurrent or progressive HCC following LRT or ST. The secondary hypothesis is that lactate-to-alanine ratios measured by DNP-MRSI can distinguish well- vs. poorly perfused tumor regions as identified on contrast-enhanced MR imaging.
Conditions
- Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC
- Hepatocellular Carcinoma (HCC)
Interventions
Hyperpolarized 1-13C -PyruvateDrug
The 1-13C pyruvate dose for each DNP-MRSI session is approximately 0.43ml/kg of 250mM (approximate range for all studies is anticipated to be between 185-285 mM) of hyperpolarized 1-13C-pyruvate (11.9 mg/kg).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Objective:Time frame: 5 Years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.